Crossmark

Chemotherapy vs. “TKI + immunotherapy” in treatment of B-cell acute lymphoblastic leukemia harboring the RCSD1::ABL2 fusion gene

Published Online: 2024-05-29

Published Print: 2024-08

Authors

Li, Yan

Zhang, Qin

Shao, Haigang
License Information

Text and Data Mining valid from 2024-05-29

Version of Record valid from 2024-05-29
More Information

Article History

Received: 14 April 2024

Accepted: 25 May 2024

First Online: 29 May 2024

Declarations

:

: Informed consent was obtained from the patient described.

: The authors declare no competing interests.

Document is current